BioWorld MedTech

Aug. 24, 2016

View Archived Issues

Iglarlixi delay puts more eyes on PRVs as business tool

Clinical utility still a major hurdle for potential coverage of novel diagnostics

Mylan tries to deflect public shaming on social media over the cost of Epipen

Daily M&A

Appointments and advancements

Other news to note

Product briefs

MDD's Oncology Extra

Lengthy MDUFA talks yield tentative agreement between FDA, industry

Three entities representing the medical device and imaging communities are heralding a tentative agreement with the FDA for the fourth reauthorization of a medical device user fee program. Read More

FDA a good sport, clears first concussion-specific computerized tests

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...